BioNTech (NASDAQ:BNTX) Given a $150.00 Price Target by Wells Fargo & Company Analysts

Key Points

• Wells Fargo & Company has cut its price target for BioNTech from $170.00 to $150.00, maintaining an "overweight" rating, suggesting a 36.12% upside from the previous close.
• Multiple analysts have varied outlooks on BioNTech, with a consensus rating of "Moderate Buy" and an average target price of $135.91.
• BioNTech reported a quarterly revenue increase of 102.6% year-over-year, despite missing earnings estimates with a loss of ($1.60) EPS.

Wells Fargo & Company set a $150.00 price target on BioNTech (NASDAQ:BNTX - Free Report) in a research report released on Tuesday, Marketbeat.com reports. The brokerage currently has an overweight rating on the stock.

BNTX has been the subject of several other research reports. The Goldman Sachs Group initiated coverage on BioNTech in a research note on Thursday, May 29th. They set a "neutral" rating and a $110.00 price target for the company. Truist Financial reaffirmed a "buy" rating and set a $155.00 price target (up previously from $151.00) on shares of BioNTech in a research note on Tuesday, June 3rd. Morgan Stanley lifted their price target on BioNTech from $132.00 to $133.00 and gave the stock an "overweight" rating in a research note on Thursday, July 10th. Bank of America dropped their price target on BioNTech from $127.00 to $126.00 and set a "buy" rating for the company in a research note on Wednesday, July 16th. Finally, Citigroup reiterated a "buy" rating and issued a $140.00 price objective (down previously from $145.00) on shares of BioNTech in a report on Tuesday, May 6th. Five analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $135.91.

BioNTech Price Performance

NASDAQ:BNTX traded up $0.31 during trading hours on Tuesday, hitting $111.66. 530,256 shares of the company's stock traded hands, compared to its average volume of 709,340. The firm has a market cap of $26.84 billion, a P/E ratio of -69.79 and a beta of 1.23. BioNTech has a 52 week low of $79.14 and a 52 week high of $131.49. The business's fifty day simple moving average is $109.40 and its two-hundred day simple moving average is $106.13. The company has a quick ratio of 10.02, a current ratio of 8.61 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX - Get Free Report) last issued its quarterly earnings results on Monday, August 4th. The company reported ($1.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.41) by ($0.19). BioNTech had a negative return on equity of 1.84% and a negative net margin of 12.20%. The firm had revenue of $306.46 million for the quarter, compared to the consensus estimate of $161.26 million. During the same period last year, the firm earned ($3.36) EPS. The company's revenue for the quarter was up 102.6% on a year-over-year basis. On average, research analysts anticipate that BioNTech will post -3.88 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in BNTX. LPL Financial LLC grew its holdings in shares of BioNTech by 4.9% during the 4th quarter. LPL Financial LLC now owns 38,860 shares of the company's stock worth $4,428,000 after acquiring an additional 1,800 shares during the period. Arrowstreet Capital Limited Partnership bought a new stake in shares of BioNTech in the 4th quarter worth approximately $3,513,000. O Shaughnessy Asset Management LLC boosted its position in shares of BioNTech by 22.0% in the 4th quarter. O Shaughnessy Asset Management LLC now owns 7,600 shares of the company's stock worth $866,000 after purchasing an additional 1,373 shares in the last quarter. Franklin Resources Inc. boosted its position in shares of BioNTech by 3,942.1% in the 4th quarter. Franklin Resources Inc. now owns 136,786 shares of the company's stock worth $15,587,000 after purchasing an additional 133,402 shares in the last quarter. Finally, Geode Capital Management LLC boosted its position in shares of BioNTech by 1.1% in the 4th quarter. Geode Capital Management LLC now owns 101,715 shares of the company's stock worth $11,590,000 after purchasing an additional 1,063 shares in the last quarter. Hedge funds and other institutional investors own 15.52% of the company's stock.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.